Tagged with ALS

Romania Cătălin Radu of Bristol Myers Squibb (BMS) Romania explains how the Celgene acquisition is allowing the company to provide their expertise on a larger scale. He reveals how BMS has become Romanian market leader in immuno-oncology by launching new indications and therapy lines for its products in the country. He…

Czech Republic Petr Vaculík, country manager of PSI CRO, a privately owned Swiss clinical research organization (CRO), describes how the number of clinical trials is decreasing in the Czech Republic, although many continue to capitalize on the country’s universal healthcare system. Vaculík also shares his views on how to retain a strong…

Czech Republic Olga Starobová, medical director of Syneos Health Czech Republic, walks us through the steps put in place to ensure successful synergies during the merger between INC Research and InVentiv Health, which has created a unique company with both clinical and commercial operations under one roof. Starobová talks about her views…

Global With clinical trials having become extremely expensive to conduct, industry buzz around the potential of data and artificial intelligence (AI) to allay these costs has grown. However, experts are split as to the true potential of digital tools to reduce clinical development outlay and provide better patient outcomes in the…

Belgium Luxembourg Brecht Vanneste, associate VP and managing director of MSD in Belgium and Luxembourg, highlights the strategic significance of the affiliate as an important location for early-stage clinical trials and home to the company’s Heist-op-den-Berg production facility, a key manufacturing site for the global group. Vanneste delivers a strong message about…

Romania László Attila, president of the Committee of Public Health of Romania, highlights the Committee’s efforts to mitigate the detrimental effects of Romania’s looming demographic crisis and medical “brain-drain”. Furthermore, he evaluates the country’s success in increasing the healthcare budget and emphasizes the importance of stable legislation.   Romania has the…

China Bing Xu, GM of Vital River Laboratories, shares the company’s development in the last 20 years; the challenges of advantages of their JV with Charles River Laboratories; the importance of lab animals for the research & development of new drugs and therapies; their core capabilities and competitive advantage as the…

Mexico Dr David Kershenobich Stalnikowitz, director-general of the Salvador Zubirán National Institute of Medical Sciences and Nutrition (INCMNSZ) shares the many new initiatives the Institute has introduced in the past couple of years, the new focus on primary care provision in line with government priorities, and the ongoing construction of their…

USA Annual numbers of new molecular entities (NMEs) and biologics license applications (BLAs) approved by the FDA’s Center for Drug Evaluation and Research (CDER). Approvals of products such as vaccines and gene therapies by the Center for Biologics Evaluation and Research (CBER) are not included in this drug count. Made with…

Europe An overview of the types of new medicines recommended for approval by the European Medicines Agency (EMA) in 2019. Made with Visme Infographic Maker     A full list of the medicines recommended for approval by the EMA in 2019 Made with Visme Infographic Maker  

Hungary According to Peter Holchacker, director general of Hungary’s Association of Innovative Pharmaceutical Manufacturers (AIPM), “clinical trials initiated by multinational companies, represent, on average, an investment of approximately EUR 300 million each year.” Furthermore, Dr György Bodoky, founder and honorary president of the Hungarian Society of Clinical Oncology (MKOT), adds that…

UK  A new report from the UK BioIndustry Association (BIA) asserts that the UK biotech industry is booming, despite Brexit uncertainties. Financing raised by UK biotechs in 2019 was down on the record year of 2018, but up on 2016 and 2017. Made with Visme Infographic Maker   A longer term perspective…